Connection

Michael Gold to United States

Back to Details
This is a "connection" page, showing publications Michael Gold has written about United States.
Michael Gold
Connection Strength
1.009
United States
  1. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.080
  2. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
    View in: PubMed
    Score: 0.072
  3. Anesthesia for subcutaneous implantable cardioverter-defibrillator implantation: Perspectives from the clinical experience of a U.S. panel of physicians. Pacing Clin Electrophysiol. 2018 07; 41(7):807-816.
    View in: PubMed
    Score: 0.063
  4. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.057
  5. Economic Value and Cost-Effectiveness of?Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 03; 5(3):204-212.
    View in: PubMed
    Score: 0.057
  6. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.055
  7. Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
    View in: PubMed
    Score: 0.047
  8. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.043
  9. Is defibrillation testing of ICDs necessary? Nat Rev Cardiol. 2012 Nov; 9(11):618-9.
    View in: PubMed
    Score: 0.043
  10. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.042
  11. Economic implications and cost-effectiveness of implantable cardioverter defibrillator and cardiac resynchronization therapy. Heart Fail Clin. 2011 Apr; 7(2):241-50, ix.
    View in: PubMed
    Score: 0.038
  12. Response to Coceani: Has CRT earned a class I recommendation? Circ Heart Fail. 2010 Jul; 3(4):559-60.
    View in: PubMed
    Score: 0.036
  13. Implantable device use in systolic heart failure: lessons learned from IMPROVE HF. Heart Rhythm. 2009 Dec; 6(12):1735-6.
    View in: PubMed
    Score: 0.034
  14. The influence of gender on arrhythmias. Cardiol Rev. 2004 Mar-Apr; 12(2):97-105.
    View in: PubMed
    Score: 0.023
  15. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2003 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.022
  16. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2002 Jan; 17(1):1-5.
    View in: PubMed
    Score: 0.020
  17. The problematic lag between FDA approval of medical devices and CMS coverage. J Cardiovasc Electrophysiol. 2021 07; 32(7):1801-1802.
    View in: PubMed
    Score: 0.019
  18. Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
    View in: PubMed
    Score: 0.019
  19. Healthcare utilization and cost in patients with atrial fibrillation and heart failure undergoing catheter ablation. J Cardiovasc Electrophysiol. 2020 12; 31(12):3166-3175.
    View in: PubMed
    Score: 0.019
  20. 2018 ACC/AHA/HRS Guideline on the?Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2019 08 20; 74(7):932-987.
    View in: PubMed
    Score: 0.016
  21. 2018 ACC/AHA/HRS guideline on the?evaluation and management of patients with bradycardia and cardiac conduction delay: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e227-e279.
    View in: PubMed
    Score: 0.016
  22. 2018 ACC/AHA/HRS guideline on the?evaluation and management of?patients with bradycardia and cardiac?conduction delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019 09; 16(9):e128-e226.
    View in: PubMed
    Score: 0.016
  23. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun; 36(6):778-92.
    View in: PubMed
    Score: 0.016
  24. Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
    View in: PubMed
    Score: 0.016
  25. Assessing outcomes in population health: moving the field forward. Am J Prev Med. 1997 Jan-Feb; 13(1):3-5.
    View in: PubMed
    Score: 0.014
  26. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 23-30; 276(16):1339-41.
    View in: PubMed
    Score: 0.014
  27. A national survey of the arrangements managed-care plans make with physicians. N Engl J Med. 1995 Dec 21; 333(25):1678-83.
    View in: PubMed
    Score: 0.013
  28. Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
    View in: PubMed
    Score: 0.011
  29. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.010
  30. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management: executive summary this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm. 2011 Jul; 8(7):e1-18.
    View in: PubMed
    Score: 0.010
  31. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm. 2011 Jul; 8(7):1114-54.
    View in: PubMed
    Score: 0.010
  32. Assessment of a novel device-based diagnostic algorithm to monitor patient status in moderate-to-severe heart failure: rationale and design of the CLEPSYDRA study. Eur J Heart Fail. 2010 Dec; 12(12):1363-71.
    View in: PubMed
    Score: 0.009
  33. Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
    View in: PubMed
    Score: 0.006
  34. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
    View in: PubMed
    Score: 0.006
  35. Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1741-3.
    View in: PubMed
    Score: 0.005
  36. Improving value measurement in cost-effectiveness analysis. Med Care. 2000 Sep; 38(9):892-901.
    View in: PubMed
    Score: 0.005
  37. No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May; 47(5):687.
    View in: PubMed
    Score: 0.005
  38. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996 Oct 16; 276(15):1253-8.
    View in: PubMed
    Score: 0.004
  39. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996 Oct 09; 276(14):1172-7.
    View in: PubMed
    Score: 0.004
  40. Use of care and subsequent mortality: the importance of gender. Health Serv Res. 1996 Aug; 31(3):347-63.
    View in: PubMed
    Score: 0.003
  41. Health insurance and subjective health status: data from the 1987 National Medical Expenditure survey. Am J Public Health. 1993 Sep; 83(9):1295-9.
    View in: PubMed
    Score: 0.003
  42. Racial differentials in the identification of hypercholesterolemia. J Fam Pract. 1993 Apr; 36(4):425-30.
    View in: PubMed
    Score: 0.003
  43. Primary care and health care reform: the next 100 days. J Fam Pract. 1993 Feb; 36(2):233-5.
    View in: PubMed
    Score: 0.003
  44. Delinquency as defense. Am J Orthopsychiatry. 1972 Apr; 42(3):463-79.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.